WO2023141522A3 - Composés multicycliques - Google Patents

Composés multicycliques Download PDF

Info

Publication number
WO2023141522A3
WO2023141522A3 PCT/US2023/060928 US2023060928W WO2023141522A3 WO 2023141522 A3 WO2023141522 A3 WO 2023141522A3 US 2023060928 W US2023060928 W US 2023060928W WO 2023141522 A3 WO2023141522 A3 WO 2023141522A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
multicyclic compounds
compounds
formula
methods
Prior art date
Application number
PCT/US2023/060928
Other languages
English (en)
Other versions
WO2023141522A2 (fr
Inventor
Sunil Paliwal
Ahmed Abdi Samatar
Lawrence Saunders CRIPE
Original Assignee
Slap Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slap Pharmaceuticals Llc filed Critical Slap Pharmaceuticals Llc
Publication of WO2023141522A2 publication Critical patent/WO2023141522A2/fr
Publication of WO2023141522A3 publication Critical patent/WO2023141522A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I), ou des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques qui comprennent un composé selon l'invention (y compris des sels pharmaceutiquement acceptables d'un composé selon l'invention) et des procédés de synthèse de ceux-ci. L'invention concerne également des procédés de traitement de maladies et/ou d'états avec un composé de formule (I), ou un sel pharmaceutiquement acceptable de celui-ci.
PCT/US2023/060928 2022-01-21 2023-01-19 Composés multicycliques WO2023141522A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263301866P 2022-01-21 2022-01-21
US63/301,866 2022-01-21

Publications (2)

Publication Number Publication Date
WO2023141522A2 WO2023141522A2 (fr) 2023-07-27
WO2023141522A3 true WO2023141522A3 (fr) 2023-08-24

Family

ID=87349160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060928 WO2023141522A2 (fr) 2022-01-21 2023-01-19 Composés multicycliques

Country Status (1)

Country Link
WO (1) WO2023141522A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055003A1 (fr) * 2002-12-13 2004-07-01 Neurogen Corporation Analogues de quinazolin-4-ylamine 2-substituee comme modulateurs des recepteurs de la capsicine
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
WO2015058160A1 (fr) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Inhibiteurs de bromodomaine
US20150291593A1 (en) * 2012-07-27 2015-10-15 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2018033815A1 (fr) * 2016-08-15 2018-02-22 Pfizer Inc. Inhibiteurs de pyridopyrimidinone cdk2/4/6
WO2020200291A1 (fr) * 2019-04-02 2020-10-08 Cullgen (Shanghai) , Inc. Composés et méthodes de traitement de cancers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004055003A1 (fr) * 2002-12-13 2004-07-01 Neurogen Corporation Analogues de quinazolin-4-ylamine 2-substituee comme modulateurs des recepteurs de la capsicine
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US20150291593A1 (en) * 2012-07-27 2015-10-15 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2015058160A1 (fr) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Inhibiteurs de bromodomaine
WO2018033815A1 (fr) * 2016-08-15 2018-02-22 Pfizer Inc. Inhibiteurs de pyridopyrimidinone cdk2/4/6
WO2020200291A1 (fr) * 2019-04-02 2020-10-08 Cullgen (Shanghai) , Inc. Composés et méthodes de traitement de cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM COMPOUND ANONYMOUS : "4-[(8-cyclopentyl-7-methoxy-5-methyl-6-oxopyrido[3,2-d]pyrimidin-2-yl)amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide", XP093087405, retrieved from PUBCHEM *

Also Published As

Publication number Publication date
WO2023141522A2 (fr) 2023-07-27

Similar Documents

Publication Publication Date Title
AU2019231551A8 (en) Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
WO2020227549A8 (fr) MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION
EP4299135A3 (fr) Dérivés de benzisoxazole sulfonamide
MX2021011606A (es) Compuestos dirigidos a prmt5.
WO2020257549A3 (fr) Composés pour le traitement de maladies pd-l1
MX2021012105A (es) Compuestos de pirrol.
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
WO2021079196A3 (fr) Modulateurs de mettl3
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
WO2003049690A3 (fr) Inhibiteurs de l'integrase du vih
MX2021007247A (es) Derivados de rapamicina.
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
WO2020210320A8 (fr) L,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones substituées
CA3156320A1 (fr) Derives de 2-azaspiro[3,4] octane utilises en tant qu'agonistes de m4
WO2020251871A3 (fr) Nouveaux composés de tétrahydroquinoléine substitués en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
MX2022004144A (es) Compuestos heterobiciclicos de arilo como bloqueadores del canal de potasio tipo shaker kv1.3.
WO2023141522A3 (fr) Composés multicycliques
WO2023158679A3 (fr) Composés inspirés de thiostrepton pour le traitement du cancer et leur préparation
MX2021014458A (es) Compuestos triciclicos.
MX2022010957A (es) Compuestos que se dirigen a las proteínas de unión al arn o a las proteínas modificadoras del arn.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23743919

Country of ref document: EP

Kind code of ref document: A2